Science, Inc. is back.
The Innovation Space’s virtual, cohort-based accelerator for early-stage science-based startups has helped launch companies like Carbon Reform and Elyte Energy since 2021. And now, it has announced the latest 11 companies to undergo its programming.
Science, Inc. offers entrepreneurial coaching, as well as access to industry and investment experts, to help startups maneuver the critical early stages of their development. In addition, eligible participating companies will have an opportunity to apply for up to $200,000 in additional support through the Innovation Space’s First Fund investment program.
“We’re excited by the growth potential in all members of this cohort,” said Bill Provine, Innovation Space founder and CEO, in a press release. “From repurposing food waste to developing medicines and technologies that will improve health outcomes, these startups are creating new solutions to some of the world’s most important and pressing needs. Our role at The Innovation Space and through our Science Inc. accelerator program is to help these startups magnify their impact and speed their trajectory to market.”
Here are the 11 startups in the 2023 cohort, with startup descriptions courtesy of The Innovation Space’s announcement:
- Cyta Therapeutics, “developing a therapeutic to treat obesity and associated cardiometabolic diseases”
- Edulis Therapeutics, “developing a minimally-invasive bioresorbable implant for localized drug delivery in patients with inflammatory bowel disease”
- EndoShunt, “a developing medical device that aims to end preventable deaths from abdominal bleeding by giving trauma surgeons the gift of time so they can give trauma patients the gift of life”
- Foogly, “a cleantech startup that uses food waste to make bioplastics and biopolymers through a one-step, eco-friendly process”
- Graftable, “developing oxygen microspheres to improve graft survival after reconstructive surgery”
- Margik, “the world’s first low-cost high-volume Organic LED platform that is enabling automotive lighting to become efficient and sustainable”
- NKA Bio, “developing therapeutic, temperature stable antibodies for critical care”
- PriZm, “a clinical-stage pediatric rare disease company developing a platform that comprises small molecule, oral therapy for treating MCT8 deficiency in pre- and post-natal babies”
- RecurX, “developed a microfluidic based diagnostic technology platform that informs the seriousness of the disease, the standard of care needed and drug treatment options”
- Serentrix, “developing non-addictive medicine for pain management”
- Sindri Materials, “an advanced materials company committed to bringing the absolute highest quality graphene into the highest impact applications through novel and proprietary manufacturing methods”
Knowledge is power!
Subscribe for free today and stay up to date with news and tips you need to grow your career and connect with our vibrant tech community.